Details for Patent: RE46791
✉ Email this page to a colleague
Which drugs does patent RE46791 protect, and when does it expire?
Patent RE46791 protects PREVYMIS and is included in two NDAs.
This patent has forty-four patent family members in thirty-six countries.
Summary for Patent: RE46791
Title: | Substituted dihydroquinazolines |
Abstract: | The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses. |
Inventor(s): | Wunberg; Tobias (Solingen, DE), Baumeister; Judith (Wuppertal, DE), Betz; Ulrich (Wuppertal, DE), Jeske; Mario (Wuppertal, DE), Lampe; Thomas (Dusseldorf, DE), Nikolic; Susanne (Monheim, DE), Reefschlager; Jurgen (Oldenburg, DE), Schohe-Loop; Rudolf (Wuppertal, DE), Sussmeier; Frank (Wuppertal, DE), Zimmermann; Holger (Wuppertal, DE), Grosser; Rolf (Leverkusen, DE), Henninger; Kerstin (Wuppertal, DE), Hewlett; Guy (Wuppertal, DE), Keldenich; Jorg (Wuppertal, DE), Lang; Dieter (Velbert, DE), Nell; Peter (Wuppertal, DE) |
Assignee: | AICURIS ANTI-INFECTIVE CURES GMBH (Wuppertal, DE) |
Application Number: | 14/682,512 |
Patent Claim Types: see list of patent claims | Use; Compound; Process; |
Drugs Protected by US Patent RE46791
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merck Sharp Dohme | PREVYMIS | letermovir | SOLUTION;INTRAVENOUS | 209940-001 | Nov 8, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
Merck Sharp Dohme | PREVYMIS | letermovir | SOLUTION;INTRAVENOUS | 209940-002 | Nov 8, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
Merck Sharp Dohme | PREVYMIS | letermovir | TABLET;ORAL | 209939-001 | Nov 8, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
Merck Sharp Dohme | PREVYMIS | letermovir | TABLET;ORAL | 209939-002 | Nov 8, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: RE46791
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Germany | 103 19 612 | May 2, 2003 |
International Family Members for US Patent RE46791
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 044078 | ⤷ Try a Trial | |||
Austria | 355280 | ⤷ Try a Trial | |||
Australia | 2004233978 | ⤷ Try a Trial | |||
Brazil | PI0410029 | ⤷ Try a Trial | |||
Canada | 2524069 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |